All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-05-14T08:32:10.000Z

Three-year follow-up results from the phase III RAY trial: ibrutinib vs temsirolimus for MCL

May 14, 2018
Share:

Bookmark this article

On February 2018, Professor Simon Rule from Plymouth University Medical School, UK and colleagues, in a letter to the editor of Leukemia, published the final 3-year follow-up results from the RAY phase III clinical trial (NCT01646021). This randomized, open-label study evaluated the efficacy and safety of ibrutinib versus temsirolimus for mantle cell lymphoma patients (MCL), who have previously relapsed from first-line therapy. The results of RAY indicated the superiority of ibrutinib over temsirolimus for MCL, in regards to efficacy, with ibrutinib-mediated progression-free survival (PFS) being significantly higher than that with temsirolimus (14.6 vs 6.2 months, HR 0.43, 95% CI [0.32–0.58]).

Key points

  • Median follow-up: 38.7 months
  • At this time 24% of ibrutinib-treated patients vs 0 temsirolimus-treated patients remained on the initial randomized treatment
  • Fifty-five patients (39%) from the temsirolimus group, crossed over to ibrutinib treatment
  • Disease progression or relapse was the most common reason for discontinuation for both groups (ibrutinib, 56% vs temsirolimus, 47%)
  • Fewer patients discontinued treatment due to adverse events in the ibrutinib arm (9%) rather than the temsirolimus group (28%)
  • Median duration of drug exposure:
    • Ibrutinib vs temsirolimus: 14.4 vs 0 months
  • Median PFS:
    • Ibrutinib vs temsirolimus: 15.6 vs 2 months (HR 0.45, 95% CI [0.35–0.60])
    • Median PFS for ibrutinib-treated patients was significantly longer independent of the prior treatment lines
  • Median overall survival (OS):
    • Ibrutinib vs temsirolimus: 30.3 vs 5 months (HR 0.74, 95% CI [0.54–1.02])
  • Overall response rate (ORR): missing data
    • Ibrutinib vs temsirolimus: 77% vs 47% (Odds ratio 4.27, 95% CI [2.47–7.39])

In this final follow-up analysis of the RAY phase III trial, three years post-treatment, the results were consistent to the ones observed in the primary analysis. In summary, ibrutinib led to significantly longer median PFS, OS and ORR, providing strong evidence on the sustained long-term clinical benefit of ibrunitib for primary relapsed MCL patients.

  1. Rule S., et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018 Feb 2. doi: 10.1038/s41375-018-0023-2. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox